Ren Min Ri Bao·2025-11-10 22:15Group 1 - Sanofi Biologics has made significant progress in a project that integrates artificial intelligence technology to enhance the stability of enzyme preparations [1] - The company is establishing a new R&D center in Changsha, Hunan, which will focus on developing biosensors, wearable devices, and high-end implantable medical devices, set to be operational by the end of this year [1] - The concentration of R&D efforts in Changsha is expected to accelerate innovation and product development [1] Group 2 - Changsha is enhancing its public innovation platform, focusing on advanced computing and artificial intelligence, as well as biomedical fields, with the establishment of key laboratories [2] - The city has signed deep cooperation agreements with local universities to promote industry-academia collaboration, facilitating technology innovation [2] - Changsha has built 18 technology transfer bases and 10 intellectual property transformation centers to support innovation [2] Group 3 - The city is optimizing its development environment to stimulate innovation, with a focus on the biomanufacturing sector [3] - A professor from Central South University has successfully commercialized over 130 independent intellectual property rights through a startup, applying technology to more than 20 companies [3] Group 4 - The government has facilitated connections between academic research and market needs, enabling efficient technology transfer within the innovation park [4] - Changsha's technology contract transaction volume has exceeded 100 billion yuan, reaching 109.528 billion yuan this year, indicating a robust innovation ecosystem [4] - The number of technology-based small and medium-sized enterprises in Changsha has surpassed 10,000, totaling 11,700 [4]